// App-Quantinova.ai

5039.0 : Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).

Researchers

Presenter

  • Scot Anthony Niglio

Principal Investigators

  • Amir Mortazavi

  • Primo Lara

  • Sumanta K. Pal

  • Biren Saraiya

  • Lisa M. Cordes

  • Lisa Ley

  • Olena Sierra Ortiz

  • Jacqueline Cadena

  • Carlos Diaz

  • Mohammadhadi H. Bagheri

  • Seth M. Steinberg

  • Rene Costello

  • Howard Streicher

  • John Wright

  • Howard L. Parnes

  • Yang-Min Ning

  • Donald P. Bottaro

  • Andrea B. Apolo

Medical Centers

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • Arthur G. James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, OH

  • University of California, San Francisco, CA

  • City of Hope Comprehensive Cancer Center, Monrovia, CA

  • Division of Medical Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, Lawernceville, NJ

  • National Institute of Health, Bethesda, MD

  • Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD

  • National Cancer Institute, Bethesda, MD

  • Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, MD

  • Biostatistics and Data Management Section, CCR, National Cancer Institute, Bethesda, MD

  • Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD

  • CCR, NIH, Bethesda, MD

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • U.S. Food and Drug Administration, Silver Spring, MD

  • Center for Cancer Research, Division of Cancer Treatment and Diagnosis, Bethesda, MD

  • Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute at the National Institutes of Health, Bethesda, MD

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Expansion Study

Phase

  • NA

Study Id's

  • NCT02496208

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved